University of Michigan to use AI, bioinformatics for personalized breast cancer care

Jessica Kim Cohen - Print  | 

Ann Arbor-based University of Michigan Comprehensive Cancer Center joined forces with Tempus, a health technology company focused on personalized oncology care, to improve breast cancer treatment.

Tempus will use bioinformatics and machine learning to analyze molecular, phenotypic, therapeutic and outcomes data for hundreds of breast cancer patients. Tempus and U-M researchers will analyze this data alongside the university's patient-derived biological models, which alert providers to the drugs that will prove most effective for individual patients.

This agreement marks U-M's second collaboration with Tempus. The organizations partnered to bring U-M's DNA-sequencing panel, MI-ONCOSEQ, to cancer patients across the country in October.

More articles on health IT:
House allocates $65M to modernize VA EHRs
Philips opens 1st innovation center in Russia
69% of organizations don't routinely test security controls, survey finds

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.